Press Release
G2GBio has the best subject matter experts in the field of the injectable drug development.
-
G2GBIO reveals data showing three-month sustained efficacy of its obes..G2GBIO, a company specializing in the development of sustained-release formulations, announced its p..
2025.11.05 -
G2GBio to accelerate its CDO·CDMO businesses with new patent for micr..The company has advanced a new platform for peptide drugs, demonstrating over 60% drug loading ..
2024.08.12 -
G2GBio has been selected for a government-supported project by the Min..G2GBio has been selected for a government-supported project by the Ministry of SMEs and Start..
2024.04.30 -
G2GBio Registers Japanese Patent for 'Mass Production Manufacturing Pl..G2GBio Registers Japanese Patent for 'Mass Production Manufacturing Platform Technology for Sustaine..
2024.04.23 -
G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58..G2GBio, Raises KRW 21.8 Billion in Pre-IPO Funding, Accumulates KRW 58 Billion in Total Investments,..
2023.11.17 -
Development of a one-month extended-release subcutaneous donepezil inj..Development of a one-month extended-release subcutaneous donepezil injection... "World's first...
2023.10.16 -
The Spectacular Rookie Venture Company The sustained-release post-oper..The Spectacular Rookie Venture CompanyThe sustained-release post-operative pain treatment has ..
2023.09.21 -
"G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development .."G2GBio Announces Once-Monthly Semaglutide (GB-7001) Development Results at American Diabetes A..
2023.06.29